Investors Careers FAQ Contact COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS ViaCyte’s Product Pipeline PEC-Encap (VC-01) ViaCyte is developing the PEC-Encap product candidate as a functional cure for type 1 diabetes. For PEC-Encap, the pouch is designed to fully contain the implanted cells but still allow vital nutrients and proteins, such as oxygen, glucose, insulin, and other hormones, to travel between the cells inside the device and the blood vessels, which grow along the outside of the device. This device is also designed to prevent immune cells from directly contacting the implanted cells so they may thrive and function without provoking an immune response or being destroyed. In the case of PEC-Encap, the Encaptra® system has generally prevented immune rejection and immune sensitization and effectively protects implanted cells from the patient’s adaptive immune system. Approximately 1.25 million people in the United States have type 1 diabetes (statistics from JDRF). Worldwide, an estimated 42 million people have type 1 diabetes (~10% of 420 million cases of all forms of diabetes, IDF). The PEC-Encap product candidate is also in clinical trials and is being developed as a functional cure for patients with type 1 diabetes. COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS CONTACT Copyright 2021 ViaCyte, Inc. All Rights Reserved Terms of Service Privacy Policy We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT